"Up to 85% of Acanthamoeba Keratitis cases are associated with contact lens wearing"
“Acanthamoeba is a free living protozoan that is present in air, soil and water”
“Although incidence is low, AK is a potentially devastating ocular infection which can cause blindness”
“The project will run for 60 months and is part of the Global International Rare Diseases Research Consortium efforts to deliver 200 new therapies by 2020”

ODAK is a European FP7 project for the pharmaceutical development of an orphan drug for the rare ocular disease Acanthamoeba Keratitis.



Our Vision

Orphan drug for Acanthamoeba Keratitis

To develop a safe and effective drug for the treatment of the rare eye disease Acanthamoeba Keratitis.

This debilitating infectious disease is caused by a commonly occurring protozoan and in the absence of treatment can result in blindness. There are currently no approved drugs to treat this disease.

The ODAK project will undertake preclinical and clinical research on the Orphan Drug PHMB (Polyhexanide) with the aim of developing the first approved drug for the treatment of this debilitating disease.

PHMB has received the orphan drug designation (EU/3/07/498) according to EC regulations 141/2000.

Learn More

Latest News & Events

ODAK European Consortium